Development of the Macrophage Activation Syndrome Collaborative

Project Period:

Grant Category:
Small Grant

Disease Area:

Hyperinflammation is the term often used to describe a type of life-threatening systemic inflammation that can occur due to genetic defects, infections, rheumatic diseases, cancers, etc. Understanding the factors driving hyperinflammation is critical for treating it properly, but these are difficult to appreciate in any given patient. Previously, levels of the inflammatory proteins “CXCL9” (a biomarker of Interferon-gamma, IFNg, activity) and “IL-18” to distinguish between different causes of hyperinflammation. In this proposal, we will develop a collaborative of five CARRA sites active in hyperinflammation research to collect the earliest samples and test how diagnostically useful IL-18 and CXCL9 are in a more “real-world” scenario. This project will build this collaborative and collect and store a diverse set of samples and clinical data. Long-term, we hope to establish processes that could be rolled out CARRA-wide and build the scientific and logistical foundations for treatment studies that target IL-18 and IFNg.


Scott W. Canna, MD

The Children's Hospital of Philadelphia

Related Awarded Grants

Disease Area:
Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Scleroderma, Juvenile Myositis, LUPUS, Rheumatoid Arthritis

Implementing a Change Package for Depression Screening and Appropriate Response for Children with Rheumatic Disease

Disease Area:
Juvenile Idiopathic Arthritis (JIA), Fibromyalgia, Pain

Initial Validation of the Pain and Symptom Assessment Tool in Juvenile Fibromyalgia Syndrome